Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 8.94
-0.23 (-2.51%)
Jul 28, 2026, 4:08 PM HKT
Ascletis Pharma Employees
Ascletis Pharma had 202 employees as of December 31, 2025. The number of employees decreased by 29 or -12.55% compared to the previous year.
Employees
202
Change (1Y)
-29
Growth (1Y)
-12.55%
Revenue / Employee
11.17K HKD
Profits / Employee
-1.98M HKD
Market Cap
9.49B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -29 | -12.55% |
| Dec 31, 2024 | 231 | 12 | 5.48% |
| Dec 31, 2023 | 219 | -59 | -21.22% |
| Dec 31, 2022 | 278 | 12 | 4.51% |
| Dec 31, 2021 | 266 | 10 | 3.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Everest Medicines | 812 |
| Lepu Biopharma | 710 |
| Alphamab Oncology | 498 |
| Suzhou Ribo Life Science | 407 |
| CARsgen Therapeutics Holdings | 355 |
| Abbisko Cayman | 276 |
| HBM Holdings | 272 |
Ascletis Pharma News
- 1 day ago - Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model - PRNewsWire
- 13 days ago - Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30 - PRNewsWire
- 5 weeks ago - Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity - PRNewsWire
- 7 weeks ago - Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39 - PRNewsWire
- 2 months ago - Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) - PRNewsWire
- 3 months ago - Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions - PRNewsWire
- 3 months ago - Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes - PRNewsWire
- 4 months ago - Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development - PRNewsWire